TriSalus Life Sciences Appoints New Auditor
Ticker: TLSIW · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
TriSalus swapped auditors, PwC is in, Withum is out, no drama reported.
AI Summary
TriSalus Life Sciences, Inc. announced on April 12, 2024, that it has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm. This change follows the resignation of its previous auditor, WithumSmith+Brown, PC, effective April 15, 2024. The company stated that the change in auditor was not due to any disagreements with WithumSmith+Brown, PC.
Why It Matters
A change in auditor can signal potential issues or a desire for a fresh perspective on financial reporting, which is important for investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine change of auditor and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — New independent registered public accounting firm
- WithumSmith+Brown, PC (company) — Resigned independent registered public accounting firm
- April 12, 2024 (date) — Date of the report and earliest event
- April 15, 2024 (date) — Effective date of auditor resignation
FAQ
Who has TriSalus Life Sciences, Inc. appointed as its new independent registered public accounting firm?
TriSalus Life Sciences, Inc. has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm.
When was the appointment of the new auditor effective?
The filing does not state an effective date for the appointment of PricewaterhouseCoopers LLP, but it was announced on April 12, 2024.
Who was TriSalus Life Sciences, Inc.'s previous independent registered public accounting firm?
TriSalus Life Sciences, Inc.'s previous independent registered public accounting firm was WithumSmith+Brown, PC.
When did WithumSmith+Brown, PC's resignation become effective?
The resignation of WithumSmith+Brown, PC became effective on April 15, 2024.
Were there any disagreements between TriSalus Life Sciences, Inc. and WithumSmith+Brown, PC?
The filing explicitly states that there were no disagreements between TriSalus Life Sciences, Inc. and WithumSmith+Brown, PC.
Filing Stats: 1,268 words · 5 min read · ~4 pages · Grade level 14.1 · Accepted 2024-04-15 17:43:19
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
- $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke
Filing Documents
- tm2411884d1_8k.htm (8-K) — 38KB
- tm2411884d1_ex16-1.htm (EX-16.1) — 2KB
- 0001104659-24-047373.txt ( ) — 258KB
- tlsi-20240412.xsd (EX-101.SCH) — 3KB
- tlsi-20240412_def.xml (EX-101.DEF) — 26KB
- tlsi-20240412_lab.xml (EX-101.LAB) — 36KB
- tlsi-20240412_pre.xml (EX-101.PRE) — 25KB
- tm2411884d1_8k_htm.xml (XML) — 5KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On April 12, 2024, the Audit Committee (the "Audit Committee") of the Board of Directors of TriSalus Life Sciences, Inc. (the "Company") approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm. On April 12, 2024, KPMG was informed that they were dismissed. KPMG's audit reports on the Company's consolidated financial statements as of and for the years ended December 31, 2023 and 2022, did not contain any adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except as follows: KPMG's report on the consolidated financial statements of the Company as of and for the years ended December 31, 2023 and 2022 contained a separate paragraph stating that "the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and needs to raise additional equity or debt to fund its operations. These matters raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty." During the Company's two fiscal years ended December 31, 2023, and the subsequent interim period through April 12, 2024, there were no: (1) "disagreements" (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KPMG, would have caused KPMG to make refe
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 16.1 Letter from KPMG LLP to the SEC, dated April 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRISALUS LIFE SCIENCES, INC. By: /s/ Sean Murphy Sean Murphy Chief Financial Officer Dated: April 15, 2024